Ro Offers Eli Lilly's Foundayo, the Newest GLP-1 Innovation Foundayo gives patients a new once daily pill option and expands Ros comprehensive weight loss formulary April 9, 2026 Ro, the leading direct-to-patient healthcare company, today announced eligible patients can now access Foundayo (orforglipron) Eli Lilly Companys newest oral GLP-1 innovation on the Ro platform, adding to Ros already comprehensive formulary of FDA-approved GLP-1s
Patches deliver medication through the skin over extended periods, with application site affecting absorption rate similar to injection sites
Can you use SingleCare for GLP-1s if on Medicaid
We will cover which GLP-1 medications Anthem covers, which plans include weight loss coverage, how to navigate prior authorization, what to do when you get denied, and the alternative paths forward when insurance says no
Traumatic joint injury is another risk factor for the development of OA (post-traumatic osteoarthritis [PTOA]), associated with earlier disease onset than age-related OA and more readily affecting younger patients [6]